PLCH1
protein-codingphospholipase C eta 1, the group of EF-hand domain containing|Phospholipases|C2 domain containing phospholipases
Gene summary
PLCH1 is a member of the PLC-eta family of the phosphoinositide-specific phospholipase C (PLC) superfamily of enzymes that cleave phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to generate second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Hwang et al., 2005 [PubMed 15702972]).[supplied by OMIM, Jun 2009]
- PLCL3
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~369.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0030886
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0030886
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0030886
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PLCH1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_014996.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 16 | 17 | |||
| missense | 223 | 6 | 3 | 232 | ||
| nonsense | 1 | 1 | ||||
| start loss | 0 | |||||
| frameshift | 1 | 1 | ||||
| splice donor/acceptor (+/-2bp) | 3 | 3 | ||||
| Total | 2 | 0 | 227 | 22 | 3 | 254 |
Highest pathogenic variant AF is 0.0000049570717
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_055811.2 | 22 | MANE Select | |
| Ensembl | ENSP00000417502.2 | 22 | MANE Select | |
| RefSeq | NP_001124432.1 | 23 | Standard | |
| RefSeq | NP_001124433.1 | 23 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Inositol phosphate metabolism - Homo sapiens (human)
- Proton Pump Inhibitor Pathway, Pharmacodynamics
- Mesodermal Commitment Pathway
- GPR40 Pathway
- D-<i>myo</i>-inositol (1,4,5)-trisphosphate biosynthesis
Biological Process
- lipid catabolic process
- inositol trisphosphate biosynthetic process
- inositol phosphate metabolic process
- phosphatidylinositol-mediated signaling
- release of sequestered calcium ion into cytosol
Molecular Function
- phosphatidylinositol phospholipase C activity
- calcium ion binding
- calcium-dependent phospholipase C activity
Cellular Component
- cytoplasm
- cytosol
- plasma membrane
- intracellular membrane-bounded organelle
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000340059
- Coding exons
- 23
- Length
- 369488
- Individuals with no LoFs
- 125704
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 44
- Defined
- 125748
- p
- 0.000175
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.48 | 777 | 902 | 0.861 | 0.0000478 | 11177 |
| Missense (PolyPhen) | 267 | 386.69 | 0.69048 | 4774 | ||
| Synonymous | 1.07 | 309 | 334 | 0.926 | 0.0000176 | 3262 |
| Loss of Function | 6.23 | 17 | 75.4 | 0.226 | 0.00000451 | 897 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00018 | 0.00018 | rare |
| Latino/Admixed American | 0.000029 | 0.000029 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.000054 | 0.000054 | rare |
| Finnish | 0.00014 | 0.00014 | rare |
| European (Non-Finnish) | 0.00027 | 0.00025 | rare |
| South Asian | 0.00013 | 0.00013 | rare |
| Other | 0.00033 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by calcium-activated phosphatidylinositol-specific phospholipase C enzymes. {ECO:0000269|PubMed:15702972}.;
Recessive Scores
- pRec
- 0.0975
Intolerance Scores
- LoFtool
- 0.678
- RVIS EVS
- -1.07
- RVIS percentile EVS
- 7.34
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.105
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |